IMBdx offers a liquid biopsy platform that combines artificial intelligence and genomic analysis for early cancer detection and ongoing patient monitoring. Their technology enables precise screening and monitoring of various cancer types through simple blood tests, improving treatment planning and patient outcomes.
Funding
$18M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Detecting cancer early and monitoring its progression often requires invasive procedures. Traditional methods can be burdensome for patients and may not provide a comprehensive view of the disease's status.
Solution
IMBdx offers a liquid biopsy platform that uses artificial intelligence (AI) and genomic analysis to improve cancer screening and monitoring through simple blood tests. Their platform, called AlphaLiquid®, analyzes circulating tumor DNA (ctDNA) to provide insights into cancer detection, recurrence monitoring, and treatment response. The technology aims to offer a less invasive and more comprehensive approach to cancer management, potentially leading to earlier detection, more informed treatment decisions, and improved patient outcomes. The platform supports various applications, including cancer screening (CancerFind™), monitoring cancer recurrence after surgery (CancerDetect™), and monitoring of advanced cancer in patients (AlphaLiquid® 100/HRR).
Target Audience
The primary target audience includes oncologists, hospitals, research institutions, and biopharmaceutical companies involved in cancer treatment and research, as well as individuals seeking cancer screening.
Features
- AI-driven analysis of ctDNA from liquid biopsies
- Non-invasive cancer screening and monitoring
- AlphaLiquid® 100/HRR for monitoring advanced cancer patients
- CancerDetect™ for early monitoring of cancer recurrence after surgery
- CancerFind™ for cancer screening via blood tests
- Services for clinical use, biopharma, and research applications